Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia.

Trial Profile

Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2013

At a glance

  • Drugs Risperidone (Primary) ; Behavioural disorder therapies
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2011 Planned end date changed from 1 Mar 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 03 Jan 2011 Planned end date changed from 1 Mar 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 23 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top